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HTIF1, a transcription coactivator which is able to mediate
RAR activity and functionally interact with PML, is encoded
by a gene on chromosome 7q32–34, which is a critical region
in acute myeloid leukemias (AML). With the assumption that
this gene may be related to AML, we investigated the HTIF1
DNA structure and RNA expression in leukemic cells from 36
M1–M5 AML patients (28 ‘de novo’ and eight ‘secondary’ to
myelodysplastic syndrome (MDS)). Abnormal HTIF1 DNA
fragments were never found, whereas loss of HTIF1 DNA was
observed in the patients with chromosome 7q32 deletion and
translocation, and in one case without detectable chromosome
7 abnormality. HTIF1 RNA was found in acute myelocytic leu-
kemic blasts, and was almost undetectable in normal mono-
nuclear cells. The expression varied among the patients: higher
in M1 to M3 subtypes, with the highest values in M1; low levels
were constantly observed in M4 and M5 AML. In addition,
HTIF1 was significantly overexpressed in MDS-related AML
(MDR-AML), but not in MDS. We also found that HTIF1
expression was high in myeloid cell lines. In myeloblastic HL60
and promyelocytic NB4 cells, induced to differentiate along the
monocytic–macrophage pathway by TPA or vitamin D3, HTIF1
expression decreased, whereas it was maintained at high levels
on induction to granulocytic differentiation by RA or DMSO. In
K562 cells, HTIF1 RNA levels did not change after hemin-
induced erythroid differentiation. These results suggest that
HTIF1 could play a role in myeloid differentiation, being dis-
tinctly regulated in hematopoietic lineages.
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Introduction
Regulation of gene expression is a complex multi-step process
that requires the concerted action of many factors. Among
these, the transcriptional intermediary factors (TIFs), also
designated as co-activators and co-repressors, interact with
sequence-speciﬁc transcription factors leading to modulation
of the chromatin structure and/or activity of the transcriptional
machinery.1,2 The human TIF1 (HTIF1, human transcription
intermediary factor 1) is a nuclear protein kinase,3 a TIF fam-
ily member, that has been identiﬁed via its interaction with
liganded nuclear receptors, including the retinoid (RXRs and
RARs) receptors.4–6 HTIF1 protein contains an N-terminal
RBCC (RING-B-box-coiled-coil) protein–protein interaction
motif,4,7 which is present in many proteins with diverse func-
tions,8,9 including PML, the protein fused to RAR in the APL
subtype of myeloid leukemia.10–13 It has recently been demon-
strated that in the myeloid differentiation PML acts as a ligand-
dependent coactivator of RAR/RXR, by interacting with
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TIF1 and CBP, in a RA-dependent transcription complex.14
In addition, HTIF1 like PML, is characterized by tumor and
growth suppression activities,13–14 and is a partner in fusion
genes: with a truncated B-Raf gene in murine hepatocellular
carcinoma,4,15 and with a truncated RET gene in thyroid
papillary carcinoma.16
Recently, the HTIF1 gene has been mapped to chromo-
some 7q32–34,17 which is a critical region of gene loss asso-
ciated with myeloid disorders.18–21 In particular, whole or par-
tial losses of chromosome 7 are strongly associated with a
dismal outcome of acute myeloid leukemia (AML).22,23 This
is a heterogeneous disease, which is caused by a variety of
pathogenetic mechanisms and characterized by variability in
the degree of the commitment and differentiation of the
myeloid lineage.23 AML may derive from a preleukemic con-
dition, the myelodysplastic syndrome (MDS).24 MDS related
AML (MDR-AML) and true ‘de novo’ AML (TDN-AML) share
morphological and clinical characteristics, but they differ in
other aspects, such as incidence throughout life, hematopo-
ietic lineage involvement, cytogenetic features, response to
therapy and incidence of relapse which is higher in MDR-
AML.24
The most frequent chromosomal abnormalities identiﬁed in
MDS are isolated losses of 5q, 20q and Y chromosome, and
a variety of chromosome 7 abnormalities (monosomy 7 and
rearrangements of 7q22, 7q32 and 7q36),25,26 which are asso-
ciated with a poor prognosis.27 Speciﬁc oncogene or a tumor
suppressor gene located on 7q could play a role in MDS25,26
and, in general, in myeloid diseases. Therefore, because of
the location on chromosome 7q, and the above mentioned
characteristics shared with PML, HTIF1 could be one of the
genes involved in the pathogenesis of AML. In this study the
HTIF1 DNA structure and RNA expression have been inves-
tigated in both MDR-AML and TDN-AML patients and in
leukemia cell lines.
Materials and methods
Patients and cell lines
Samples of bone marrow (BM, 36) and peripheral blood (PB,
13) were obtained from 36 AML patients, 28 of whom
presented with de novo AML, and eight who had evolved
from an antecedent MDS. This series included 16 males (ages
30–79, mean 64) and 20 females (ages 32–88, mean 61). BM
and PB were analyzed in control cases (four healthy males
and four females) and in 10 patients with MDS (four males
and six females). Diagnosis was based on morphological,
clinical and immunological criteria. Conventional cytogenetic
analysis was performed in 34 AML cases showing the follow-
ing clonal abnormalities: chromosome 7 abnormalities in nine
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cases (ﬁve with MDR-AML); t(15;17) in ﬁve; +13 in three; t(8;
21) in two; +11, 5q−, 9q−, t(6;11), i(Xq) in one patient each.
There were normal karyotypes in six patients and no mitoses
in the remaining four.
Cell lines (myeloblastic HL-60, promyelocytic NB4,
erythroleukemic K562, B-lymphoid Raji and EBV-immor-
talized lymphoblastoid) were studied. The differentiating
agents used were 16 nM 12-O-tetradecanoylphorbol 13-ace-
tate (TPA) and 100 nM 1,25-dihydroxyvitamin D3 (D3)
(monocyte/macrophage pathway), 1.25% dimethylsulphoxide
and 1 M all-trans retinoic acid (RA) (granulocytic pathway),
and 30 M hemin (erythroid pathway), as previously
described.28,29 Cell differentiation into neutrophils and mono-
cytes was assessed by morphology. Macrophage-like differen-
tiation induced by TPA was assessed by adhesion of the cells
to the tissue culture plastic and by the morphology of the
adherent cells.
Figure 1 Southern blot analysis of HTIF1 DNA in AML. (a) Schematic representation of HTIF1 cDNA. E: EcoRI restriction sites. The a and
b arrows indicate the previously reported breakpoint sites.15,16 The HPRR-1 probe was produced by RT-PCR using primers HPRR-F2:
5-AAGACCACACTGTCAGACAG-3 and HPRR-R2: 5-ATTCTGTTCCACGACAGGAT-3 on reverse-transcribed HL60 cell total RNA. HPRR-2
is a cDNA probe.7 (b) DNA from PB (asterisk) and BM samples of leukemic (AML) and non-leukemic (C) cases were restricted with BamHI or
EcoRI enzymes. Patient numbers correspond to cases indicated in Figure 2a and Table 1, with the exception of No. 34, an AML M1 patient
showing a –7 chromosome abnormality. After gel fractionation and blotting of the DNA, ﬁlters were hybridized with HPRR probes and rehy-
bridized with the bcl-1 pB probe for the major cluster region, as previously described.32 The amount of HPRR DNA was related to that of total
DNA and bcl-1 DNA. Reduction in HPRR-speciﬁc bands was found in cases 34, 11, 8 and 32. In the latter case a marked reduction in HTIF
DNA was detected with the HPRR-1, and not with the HPRR-2 probe. Similar restriction patterns were observed in PB and BM samples when
available, as shown for case 11.
Leukemia
DNA and RNA extraction and analysis
Experiments were carried out on cultured cells and patient
blast cells obtained by Ficoll separation. Nucleic acid extrac-
tion, Southern and Northern blotting were performed as pre-
viously described.30–32 Filters were hybridized with the probes
shown in Figure 1a: HPRR-1 (a 750 bp RT-PCR-derived probe)
and HPRR-2 (a 1.5 kb EcoRI-EcoRI cDNA fragment).7 The
amount of RNA was assessed by hybridization with a GAPDH
gene probe,32 and level of gene expression was determined
by densitometric analysis. TIF1 expression values were
deﬁned by the TIF1/GAPDH ratio.
Statistical analysis
Data are expressed as the mean ± s.e.m. Statistical analysis
was performed using the unpaired and paired Student’s t-test,
as applicable.
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Figure 2 HTIF1 gene expression in AML patients. (a) Northern blot of HTIF1 RNA in BM samples from AML patients. Total RNA from
two cases for each FAB subtype are shown. Patient numbers correspond to those indicated in Figure 1b and Table 1. PBL, normal peripheral
blood lymphocytes; BMM, normal bone marrow mononuclear cells; BM, whole normal bone marrow; PB, whole normal peripheral blood.
After hybridization with the 32P-labelled HPRR-2 probe, ﬁlters were rehybridized with the 32P-labelled GAPDH probe (see Methods). (b) Mean
± s.e.m. of HTIF1 expression level in each AML FAB subtype. Only BM samples were included in this analysis.
Results
Loss of HTIF1 DNA in AML with abnormal
chromosome 7q
The HTIF1 gene was analyzed in 23 AML cases by Southern
blotting, after restriction with BamHI and EcoRI, and hybridiz-
ation with the HPRR-1 and HPRR-2 c-DNA probes (Figure 1a).
The probes cover 75% of the HTIF1 coding sequences
including the two breakpoints associated with previously
reported TIF gene rearrangements.4,15,16 No rearrangements
were detected within the 50 kb region of the HTIF1 ana-
lyzed. However, weaker bands were found in patients with
monosomy 7 or deletion of 7q32 consistent with loss of one
allele as expected, but also in cases with translocation involv-
ing 7q32 band (cases 34, 11 and 8, respectively, see Figure
1b). No abnormality was observed in the case with a translo-
cation involving 7q22 (patient 12). In case 32, an AML M5
patient with no detectable abnormality of chromosome 7, a
marked reduction in TIF DNA was detected with the HPRR-
1 probe, and not with the HPRR-2, suggesting a partial loss
of the gene.
Variable HTIF1 RNA expression in AML patients
Considering the possibility that small mutations, which are
undetectable by Southern blotting, could lead to abnormal
transcripts, HTIF1 expression was analyzed by Northern
blotting in 33 AML cases and in a series of hemopoietic cell
lines. Only the expected transcript of approximately 4.2 kb in
size was detected with both probes in all the AML cases
(Figure 2a). Surprisingly, the HTIF1-speciﬁc band was almost
undetectable in mononuclear cells obtained by separation
over a Ficoll gradient of normal peripheral blood (PB) and
bone marrow (BM) samples. However, it was present in nor-
mal whole (PB) and (BM) samples containing a majority of
neutrophilic cells.
In the AML patients, HTIF1 expression was speciﬁcally
related to the FAB subtype (Figure 2b and Table 1): the mean
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AML MDS Nor
(1–10) (2–8)
M0 M1 M2 M3 M4 M5
(1–4) (5–10) (11–18) (19–23) (24–27) (28–33)
TDN-AML 1.7 2.5 1.7d 2.2 1.1 0.7 0.0 0.0
(25) 2.2 10.4 2.2t 3.8 2.2 1.3 0.3 0.0
4.3 11.3 2.5 6.6 3.3 2.6 0.5 0.0
2.6d 6.8 2.8 2.6 0.5 0.5
6.0 10.6 0.7 0.5
6.5 1.0 1.1
1.4 1.5
1.6
1.8
2
MDR-AML 6.0m,d,t 6.1t 5.5 1.2
(8) 16.5m 18t 3d
23
Total 3.5 ± 0.8 11.6 ± 2.6 5.6 ± 1.8 6.0 ± 1.4 2.3 ± 0.5 1.9 ± 0.3 (P = 0.004) 0.98 ± 0.22 0.51 ± 0.2
(Mean ± s.e.m.)
Total
TDN-AML 2.7 ± 0.6 8 ± 2.2 3.5 ± 0.7 6.0 ± 1.4 2.3 ± 0.5 1.8 ± 0.4 4 ± 0.6
(Mean ± s.e.m.)
MDR-AML 6.0 15.2 ± 3.9 11.7 ± 4.3 2.1 ± 0.6 9.9 ± 2.6
(Mean ± s.e.m.)
TDN-AML vs 0.4
MDR-AML (P = 0.002)
Values represent the amount of HTIF1 RNA in mononuclear cells from patients (AML, MDS) and control subjects (Nor) that are indicated
by numbers in italics (see Methods for technical details). M1–M5 indicate FAB AML subtypes. Patient cases 3, 6–12, 15, 17, 18, 20, 22–
24, 28, 30, 32, have been analyzed by Southern blotting. m, −7; d, del(7q), t, translocations involving 7q. MDS patients include one RAEBt
(1) and two CMML (2, 3).
value of expression was higher in M1 (11.6 ± 2.6), ﬁve times
lower in M5 subtype (1.9 ± 0.3) (P = 0.003), and 20 times
lower in normal samples. In BM and PB samples from 11
patients, HTIF1 displayed a comparable expression. No
association with patient age or sex was observed. The data
indicate a decrease in HTIF1 expression with monocytic dif-
ferentiation, in agreement with the undetectability of HTIF1
expression in normal mononuclear cells, including monocytes
and lymphocytes.
Different HTIF1 RNA expression in myeloid and
lymphoid cell lines
The detection of HTIF1 RNA in myeloid cells led us to inves-
tigate whether it was related to a speciﬁc cell lineage, and we
examined the gene expression in myeloid and lymphoid cell
lines. A marked HTIF1 expression was observed in myeloid
HL-60, NB4 and K562 cells, a clearly lower level in B lymph-
oid Raji cells and an almost undetectable level in two B-lym-
phoblastoid cell lines (LCL 1 and 2) (Figure 3). This result con-
ﬁrms a prevalence of HTIF1 expression in myeloid vs B-
lymphoid cells.
HTIF1 RNA is markedly down-regulated in TPA-
induced macrophage differentiation
The possible relation between HTIF1 expression and cell dif-
ferentiation was investigated in cells treated with differen-
tiating agents (Figure 4a and b).
Leukemia
Figure 3 HTIF1 gene expression in hematopoietic cell lines.
Northern blot of HTIF1 RNA in various hematopoietic cell lines.
Acute promyelocytic leukemia, NB4; acute myeloblastic leukemia,
HL60; chronic myeloid erythro-leukemia, K562; B lymphoid cells:
Raji; B-lymphoblastoid cell line: LCL1 and LCL2. See Methods and
legend of the previous ﬁgure for technical details.
Treatment of HL60 cells for 48 h with 16 nM TPA, that com-
mits the cells to macrophage-like lineage, markedly reduced
HTIF1 mRNA levels (Figure 4a). Compared to untreated
cells, HTIF1 RNA values found in adherent and non-adher-
ent cells were 10 and three times lower, respectively (a and
n a of Figure 4a); similar, but less pronounced results were
obtained in NB4 cells (Figure 4b).
Treatment of HL60 and NB4 cells for 5 days with 100 nM
D3, that is reported to commit HL60 cells to monocytic differ-
entiation,28,33,34 induced only minimal changes in mor-
phology and cell growth (cell counts were 75 and 85% of
HTIF1 gene expression in human AML
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Figure 4 Decrease in HTIF1 expression upon monocytoid–macrophage differentiation of HL60 and NB4 cells. (a) Autoradiograms of a
Northern blot of total RNA from HL60, NB4 and K562 cells, untreated (−) and treated (+) with differentiating agents (TPA, D3, RA, DMSO,
Hemin, as described in Materials and methods). Filters were hybridized with the HTIF1 HPRR-2 probe and subsequently re-hybridized with
GAPDH probe, c-myc or -globin probes, as previously described.32,29 a and n a indicate adherent and non-adherent cells. (b) Mean values
(± s.e.m.) of HTIF1/GAPDH RNA ratios in treated and untreated cells, from at least three different experiments.
control values). c-myc RNA levels, that were down-regulated
by TPA, remained unchanged after treatment with D3, as
shown in Figure 4a. Nevertheless, in both cell types, a
reduction in HTIF1 RNA levels was observed in treated cells.
Treatment of HL60 and NB4 cells for 4 days with 1 M RA,
that commits cells to granulocyte-like differentiation,28,35,36
produced signiﬁcant morphological changes (about 50–70%
of the cells aggregated to form clusters), a reduction in cell
proliferation (55 and 45% of control) and disappearence of c-
myc RNA levels. However, a signiﬁcant reduction in HTIF1
RNA levels, relative to GAPDH RNA levels, was not observed
when compared with untreated control cells (Figure 4b).
Treatment of HL60 cells for 6 days with DMSO inducing gra-
nulocyte differentiation, did not produce a signiﬁcant
reduction in HTIF1 RNA levels (Figure 4a and b). In K562
cells induced to erythroid differentiation by treatment with
hemin for 5 days, as previously reported,29 HTIF1 RNA levels
remained unchanged while a marked increase in -globin
mRNA levels was observed (Figure 4a).
High HTIF1 RNA expression in MDR-AML
In order to evaluate whether the different level of expression
in AML subtypes could correlate with the clinical history of
the patients, we compared HTIF1 expression in TDN-AML
vs MDR-AML cases (Table 1). A total mean value of 4.0 ± 0.6
was found in TDN-AML, while a markedly higher mean value
of 9.9 ± 2.6 was found in MDR-AML, with a statistically sig-
niﬁcant difference between the subgroups (P = 0.002). Thus,
overexpression of HTIF1 appears to correlate mostly with the
MDR-AML. In the 10 cases of MDS analyzed, levels of HTIF1
expression were comparable to those of control cases (Nor,
Table 1).
Since the HTIF1 gene has been localized on chromosome
7q32–34, we considered the possible association between
HTIF1 expression and chromosome 7 abnormalities, analyz-
ing eight of the nine patients presenting the involvement of
chromosome 7 (superscript letters in Table 1), including ﬁve
MDR-AML. The abnormalities were prevalent in MDR-AML
cases, but also present in TDN-AML cases with low levels of
HTIF1 RNA expression (Table 1). Thus, high levels of HTIF1
expression seem to be a feature of the MDR-AML population,
regardless of the presence of 7q abnormality.
Discussion
TIF1 is a chromatin-associated factor with a conserved struc-
tural motif, the RBCC domain,4,8 present in fusion oncoprote-
ins like PML.9 Because of this structural similarity and the
ability of TIF1 to interact with RAR and PML,14 that have
been demonstrated to be critical proteins in growth inhibition
and myeloid differentiation,37–38 we investigated the possible
involvement of HTIF1 in AML.
Southern analysis in 23 AML cases revealed no rearrange-
ments of HTIF1, at least in the regions previously found
rearranged in a papillary thyroid carcinoma16 and hepatocel-
lular carcinoma.15 Nevertheless, the group of investigated
cases was not large enough to exclude the occurrence of
TIF1 rearrangements in AML, considering that well known
rearrangements, such as those involving DEK-CAN, occur at
a frequency lower than 4%.39 The reduction in the level of
HTIF1 DNA found in some cases appeared to correlate with
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chromosome 7q abnormalities, including loss of 7q, deletions
and translocation at 7q32 and not at 7q22, in accordance with
the mapping of HTIF1 gene to the 7q 32–34 region.17 The
partial loss of the HTIF1 DNA 5 region observed in a MDR-
AML case with no apparent chromosome 7 abnormalities,
would indicate the occurrence of a submicroscopic chromo-
some 7 lesion involving the gene. This is in accordance with
results previously reported in AML and MDS patients, demon-
strating loss of 7q by PCR-based techniques19,26 and hidden
translocations of 7q by spectral karyotyping,25 otherwise not
revealed by conventional cytogenetics. The case presented
here remains to be analyzed in more detail. In spite of this
sample, disruption of HTIF seems to be a rare event in
AML patients.
Although DNA analysis did not implicate HTIF1 gene
rearrangement as a mechanism associated with the develop-
ment of AML, the relative expression of HTIF1 RNA in leu-
kemic cells of AML patients and in myeloid cell lines, suggests
an important role of this gene in the myeloid lineage.
Previous studies have shown that TIF1 is expressed in vari-
ous human tissues, including whole peripheral blood.17 In the
mouse,40 during embryogenesis it is ubiquitously expressed
until mid-gestation, then, it remains highly expressed in
developing nervous system and within the proliferating
regions of the kidneys and teeth, whereas, in the adult, it is
predominantly expressed in both the male and female gonads.
No data are available on TIF1 expression in hematopoietic
cells. Our data show HTIF1 to be speciﬁcally expressed in
granulocytic cells, both in the PB and in the BM (Figure 2a).
In our patients HTIF1 was found to be predominantly
expressed in those leukemias reﬂecting an early and inter-
mediate stage of myeloid differentiation (M1–M3 of the FAB
classiﬁcation), in M2-derived myeloblastic HL60, in M3-pro-
myelocytic NB4 and chronic K562 myeloid cell lines. On the
contrary, low levels of expression were found in Raji B-lymph-
oid and EBV-transformed B-lymphoblastoid cell lines (see
Figure 3).
The low levels of HTIF1 RNA expression in leukemias with
predominant monocytic differentiation seem to be in accord-
ance with the reduction in HTIF1 RNA expression found in
HL60 and NB4 cells induced to differentiate down the mono-
cyte-macrophage pathway. The less pronounced reduction in
HTIF1 RNA after D3 treatment, in comparison with the TPA
treatment, might be explained by the previously observed
weak effectiveness of D3 on both leukemia cell lines;35 fur-
thermore, it has been shown that D3 or TPA in NB4 cells
treated individually, result in only a partial or incomplete dif-
ferentiation along the monocyte–macrophage pathway, and
that both are required to achieve optimal macrophage func-
tion.33 Accordingly, the down-regulation of the c-myc proto-
oncogene which parallels terminal differentiation,33,36 was not
observed in D3-treated cells (Figure 4a). HTIF1 RNA
expression was not signiﬁcantly decreased when HL60 and
NB4 cell lines differentiated along the granulocytic pathway
after treatment with DMSO or RA. However, in NB4 cells
treated with RA, down-regulation of the c-myc was observed,
associated with the decrease in cellular proliferation and pro-
gression of maturation and differentiation.
Therefore, the downregulation of HTIF1 expression in
macrophage and not in granulocytic maturation, obtained
after treatment of different cell lines with agents acting at dif-
ferent molecular levels, supports the hypothesis of a differen-
tial regulation of HTIF1 gene according to a different cell
lineage.
In myeloid differentiation PML acts as a ligand-dependent
Leukemia
coactivator of RAR/RXR, by interacting with TIF1 and
CBP, in a RA-dependent transcription complex.14 The pres-
ence of PML, therefore, is crucial for the growth-inhibitory
activity of RA, as well as for RA induction of myeloid differen-
tiation.41 Intriguingly, it has been reported that, in HL60 cells,
RA increases the level of PML.42 It is, therefore, possible that
RA could also sustain the HTIF1 expression to maintain the
cellular homeostasis of the two co-receptors.
The hypothesis of PML and HTIF1 co-expression is also
supported by the sustained levels of HTIF1 RNA detected in
K562 cells induced to erythroid differentiation (Figure 4). In
fact, PML which has been found to functionally interact with
nuclear proteins in K562 cells,43,44 appears to be highly
expressed through the erythroid pathway, as observed in
differentiating hematopoietic progenitor cells.44
Thus, HTIF1 expression appears to be not only associated
with immature proliferating cells, but also with cells deriving
from precursors with speciﬁc differentiation commitments.
Further studies of HTIF1 expression in GEMM- and GM-CFU
could conﬁrm this hypothesis.
The distinction of ‘de novo’ AML from MDS-derived AML
is extremely useful because, despite the fact that the two con-
ditions share a number of characteristics, they differ in other
aspects such as sensitivity to conventional therapy.23,24 Mor-
phological, clinical and genetic differences are valuable tools
for better differentiation of these two conditions. The obser-
vation of a signiﬁcant correlation between MDS-derived AML
and a higher level of HTIF1 expression, in comparison to the
lower level detected in TDN-AML and MDS, is of interest,
suggesting that HTIF1 expression could be a typical feature
of MDS progressing to AML and that the MDS transition to
AML could be mediated by transcriptional mechanisms
requiring high levels of HTIF1 and/or its interacting proteins.
On the other hand, deregulation of HTIF1 expression could
be associated with the abnormal DNA methylation frequently
observed in AML.45–47 For instance, methylation of p15 gene
promoter has frequently been reported in AML at presen-
tation,48 and in MDS it is highly associated with leukemic
transformation.49 However, it becomes difﬁcult to reconcile
the overexpression of HTIF1 with DNA hypermethylation
which is generally associated with gene expression silencing,
unless it occurs on a hypothetical gene encoding a repressor
of HTIF1 gene expression.
On the other hand, it has been shown that the activation of
the HOX11 proto-oncogene in T-ALL occurs in the absence
of translocation, but in association with extensive demethyl-
ation of the proximal HOX11 promoter.50 Examination of the
methylation status of the HTIF1 promoter sequence, when
available, will be necessary to verify its methylation status in
AML cases with high HTIF1 expression.
The association of myeloid leukemia with chromosomes
7−/7q−,18–22 and their involvement in MDS as a well known
negative prognostic factor,22–27 supports the concept that these
chromosomal regions contain novel tumor suppression genes.
In the AML patients examined here, chromosome 7 abnor-
malities, although prevalent in the MDR-AML cases, did not
show an invariable association with the high expression of
HTIF1 gene, located at 7q32–34.
In conclusion, the absence of abnormal HTIF1 DNA frag-
ments or transcripts suggests that gross genomic recombi-
nations of HTIF1 do not occur frequently in AML. Neverthe-
less, the differential expression in myeloid and B-lymphoid
cells, and its overexpression in some AML subtypes, strongly
indicate that the HTIF1 gene could play an important role
in myeloid differentiation. Therefore, at variance with the
HTIF1 gene expression in human AML
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housekeeping expression previously reported,17 we found that
HTIF1 gene shows a cell- and differentiation-speciﬁc
expression.
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